Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology

NEXT STORY
NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx™ Thermal Oncology System
PREV STORY
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

author_avatar
NASDAQ Market News

Genocea to Present at Two March Investor Conferences

CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer

author_avatar
NASDAQ Market News